Stephen Smolinski
Corporate Officer/Principal chez PRECIGEN, INC.
Profil
Stephen Smolinski is currently the Senior VP & Head of Business Development at Precigen, Inc. He previously worked as the Vice President of Marketing at Savient Pharmaceuticals, Inc. from 2011 to 2013, the VP & Head of North American Rheumatology Business at Genzyme Therapeutics Ltd.
from 2015 to 2017, the Global Head of Immunology Therapeutic Area at Swedish Orphan Biovitrum AB, and the Chief Commercial Officer at Avalo Therapeutics, Inc. He received his undergraduate degree from Oregon State University.
Postes actifs de Stephen Smolinski
| Sociétés | Poste | Début |
|---|---|---|
| PRECIGEN, INC. | Corporate Officer/Principal | - |
Anciens postes connus de Stephen Smolinski
| Sociétés | Poste | Fin |
|---|---|---|
| CARTESIAN THERAPEUTICS, INC. | Corporate Officer/Principal | 18/08/2020 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | 01/01/2017 |
| SAVIENT PHARMACEUTICALS INC | Sales & Marketing | 01/06/2013 |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
| AVALO THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Formation de Stephen Smolinski
| Oregon State University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| AVALO THERAPEUTICS, INC. | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| PRECIGEN, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Savient Pharmaceuticals, Inc.
 Savient Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Savient Pharmaceuticals, Inc. operates as a specialty biopharmaceutical company, which develops, manufactures and markets pharmaceutical products. The company focuses on developing and commercializing KRYSTEXXA for the treatment of chronic gout in adult patients who do not respond to conventional therapy. It also sells and distributes branded and generic versions of oxandrolone, a drug used to promote weight gain following involuntary weight loss. The company was founded in 1980 is headquartered in East Brunswick, NJ. | Health Technology |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
